ClinicalTrials.gg
RecruitingNCT04389086PelvEx IIUpdated Sep 6, 2022

Induction Chemotherapy for Locally Recurrent Rectal Cancer

A Phase 3 interventional study of Combination drug and Chemoradiotherapy in Recurrent Rectal Cancer, sponsored by Catharina Ziekenhuis Eindhoven. Recruiting at 14 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-09-06.

Sponsored by Catharina Ziekenhuis Eindhoven · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2024, 2 years 8 months ago, but the record still lists the study as recruiting.
  • Started Nov 2020; still recruiting 6 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
364
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 74 studies in Rectal Neoplasms with a site in Netherlands — 21 open to participants now, 32 under way, 8 of them phase 3. Rectal Neoplasms · Netherlands.

Planned enrollment
14th of 59
364 · median 108
Started
2020
with 4 others
Phase 3
19 of 74
4 open now
Primary completion
2024-03
later than 3 of 31 live
Registered
44th of 74
by date

Among the 74 studies in Rectal Neoplasms with a site in Netherlands, this one is the 14th largest by planned enrollment of the 59 interventional ones that give a count, is one of 5 that started in 2020, is one of 19 in phase 3, reaches primary completion later than 3 of the 31 other live ones, and was the 44th registered.

Rectal Neoplasms

2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

21 of the 74 studies in Rectal Neoplasms with a site in Netherlands are open now. Recruiting first, the newest first:

15 more — sign in →

All 21 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 74 studies in Rectal Neoplasms with a site in Netherlands, or all of them as a file.
02

Study summary

This is a multicentre, open-label, parallel arms, phase IIII study that randomises patients with locally recurrent rectal cancer in a 1:1 ratio to receive either induction chemotherapy followed by neoadjuvant chemoradiotherapy and surgery (experimental arm) or neoadjuvant chemoradiotherapy and surgery alone (control arm)

03

Conditions studied

  • Recurrent Rectal Cancer

Keywords

  • Locally recurrent rectal cancer
  • Neoadjuvant therapy
  • Induction chemotherapy
  • Resection margin
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years or older
  • Confirmed locally recurrent rectal cancer after total or partial mesorectal resection for rectal or distal sigmoidal cancer either by histopathology ór clinically proven (evidence on imaging in combination with clinical findings, with consensus in MDT)
  • Resectable disease determined by magnetic resonance imaging (MRI) or deemed resectable after treatment with chemoradiotherapy.
  • WHO performance score 0-1
  • Written

Exclusion criteria

Exclusion Criteria:

  • Radiological evidence of disease (e.g. liver, lung) at time of randomisation or in the six months prior to randomisation.
  • Known homozygous DPD deficiency
  • Any chemotherapy in the past 6 months.
  • Any for the planned chemotherapy, as determined by the medical oncologist.
  • Radiotherapy in the past 6 months for primary rectal cancer.
  • Any contraindication for the planned chemoradiotherapy, as determined by the medical oncologist and/or radiation oncologist.
  • Any contraindication for surgery, as determined by the surgeon and/or anaesthesiologist.
  • Concurrent that interfere with the planned study treatment or the prognosis of resected LRRC.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
364 participants (estimated)

Study arms

  • Experimental
    Induction chemotherapy + chemoradiotherapy + surgery

    Induction chemotherapy followed by neoadjuvant chemoradiotherapy and surgery

    Drug: Combination drug · Radiation: Chemoradiotherapy · Procedure: Surgery locally recurrent rectal cancer

  • Active comparator
    Neoadjuvant chemotherapy + surgery

    Neoadjuvant chemoradiotherapy followed by surgery

    Radiation: Chemoradiotherapy · Procedure: Surgery locally recurrent rectal cancer

Interventions

  • DrugCombination drug

    Induction chemotherapy consists of either three three-weekly cycles of CAPOX (oxaliplatin 130 mg/m2 BSA IV + capecitabine 1000 mg/m2 BSA, orally, twice daily) or four two-weekly cycles of FOLFOX (85 mg/m2 BSA of oxaliplatin IV + 400 mg/m2 BSA of leucovorin IV + 400 mg/m2 BSA of bolus 5-fluorouracil IV followed by 2400 mg/m2 BSA of continuous 5-fluorouracil IV). It is left to the discretion of the treating medical oncologist which of the two will be administered. In case of (previous) unacceptable toxicity (physician's discretion) to oxaliplatin, FOLFIRI may be prescribed. FOLFIRI (180 mg/m2 BSA of irinotecan IV + 400 mg/m2 BSA of leucovorin IV + 400 mg/m2 BSA of bolus 5-fluorouracil IV followed by 2400 mg/m2 BSA of continuous 5-fluorouracil IV) consists of four two-weekly cycles. If a patient has stable or responsive disease, induction chemotherapy will be continued with either one three-weekly cycle of CAPOX or two two-weekly cycles of FOLFOX/FOLFIRI.

    Also known as: CAPOX, FOLFOX, FOLFIRI

  • RadiationChemoradiotherapy

    Concomitant chemotherapy agent: capecitabine Radiotherapy dose: full course radiotherapy consists of 25x2.0 or 28x1.8 Gy. In case of previous radiotherapy, the radiotherapy dose will consist of 15x2.0 Gy.

  • ProcedureSurgery locally recurrent rectal cancer

    Type of surgery depends on the location of the recurrence and involvement of adjacent structures and is left to the discretion of the operating surgeon. Intraoperative radiotherapy is optional.

06

What researchers measure

Primary outcomes

  1. Proportion of patients with a clear resection margin

    A resection margin is considered clear (R0), if there are no tumour cells in any of the resection surfaces as determined by microscopy (resection margin \> 0mm)

    Time frame: Scored within 1 one month of surgery

Secondary outcomes

  1. Local recurrence free survival

    Time frame: Assessed up to 5 years

  2. Progression free survival

    Time frame: Assessed up to 5 years

  3. Metastasis free survival

    Time frame: Assessed up to 5 years

  4. Disease free survival

    Time frame: Assessed up to 5 years

  5. Overall survival

    Time frame: Assessed up to 5 years

  6. Pathologic response

    Scored according to Mandard

    Time frame: Scored within 1 month of surgery

  7. Toxicity induction chemotherapy

    Adverse events grade 3 or higher according to the NCI-CTCAE v5.0

    Time frame: Scored until one month after the last administration of the chemotherapy

  8. Compliance induction chemotherapy

    Time frame: Scored within 1 month after start chemoradiotherapy

  9. Toxicity chemoradiotherapy

    Adverse events grade 3 or higher according to the NCI-CTCAE v5.0

    Time frame: Scored until 3 months after the last administration of the radiotherapy

  10. Compliance chemoradiotherapy

    Time frame: Evaluation at time of surgery

  11. Number of patients undergoing surgery

    Time frame: Surgery is scheduled 10-14 weeks after finishing chemoradiotherapy

  12. Surgical characteristics

    including data on intra-operative radiotherapy

    Time frame: Evaluation directly postoperative

  13. Major surgical morbidity

    Clavien-Dindo grade 3 or higher

    Time frame: 30 and 90-days postoperative

  14. Radiological response

    mrTRG

    Time frame: Restaging is performed after 3 cycles of CAPOX (1 cycle is 3 weeks) or 4 cycles of CAPOX/FOLFOX (1 cycle is 2 weeks). Second restaging is performed 4-6 weeks after finishing chemoradiotherapy

  15. Cancer specific quality of life

    QLQ-C30

    Time frame: at baseline, 3 months and 12 months postoperative

  16. Cost-effectiveness

    EQ-5D-5L

    Time frame: at baseline, 3 months and 12 months postoperative

  17. Colorectal cancer specific quality of life

    QLQ-CR29

    Time frame: at baseline, 3 months and 12 months postoperative

07

Study locations

8 of 14 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Participant-level datasets and statistical codes will become available upon reasonable request after the results of the study have been published.

Supporting information: Study protocol, Informed consent form

Time frame: The full protocol and Dutch informed consent forms are publicly accessible after approval of the medical ethics committee.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2020 (actual). Primary completion is estimated for Mar 2024, 39 months after the start.

Of 73 non-industry phase 3 interventional studies under Rectal Neoplasms, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 104. This study's planned 39 months is below that.

Counting every sponsor, half of 81 studies reached it within 59 months; a quarter within 37 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2020
First posted
May 15, 2020
StartActual
Nov 13, 2020
Primary completionEst.
Mar 1, 2024
CompletionEst.
Mar 1, 2030
Last update
Sep 6, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 6, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04389086
Lead sponsor
Catharina Ziekenhuis Eindhoven
Responsible party
J. W. A. Burger (MD, PhD, Catharina Ziekenhuis Eindhoven) — Principal investigator
First posted
May 15, 2020
Start date
Nov 13, 2020
Primary completion
Mar 1, 2024 (estimated)
Completion
Mar 1, 2030 (estimated)
Last update
Sep 6, 2022

Study contacts

Stefi Nordkamp, MD
Contact
stefi.nordkamp@catharinaziekenhuis.nl
0031 40 2398858
Floor Piqeur, MD
Contact
floor.piqeur@catharinaziekenhuis.nl
0031 40 2397152
Pim Burger, MD
principal investigator · Catharina Ziekenhuis Eindhoven

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion